Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine, Midazolam, and Dexmedetomidine for ACPE
NCT06653244Phase 1Completed
- Sponsor
- Menoufia University
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in acute cardiogenic pulmonary edema (CPE) comparing Group Midazolam, Group Morphine and Group Dexmedetomidine (3 arms). Primary endpoint: Clinical improvement in length of hospital stay at 48 hours. Started Apr 2024; status: completed.
02
Drugs
morphinemidazolamdexmedetomidine
03
Conditions
acute cardiogenic pulmonary edema (CPE)
Beyond the preview
Go deeper on NCT06653244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653244.